Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses

Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Hongjing, Peng, Jinwu, Zheng, Hongmei, Fan, Songqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201048/
https://www.ncbi.nlm.nih.gov/pubmed/32411591
http://dx.doi.org/10.3389/fonc.2020.00515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201048/
https://www.ncbi.nlm.nih.gov/pubmed/32411591
http://dx.doi.org/10.3389/fonc.2020.00515

Ejemplares similares